Status:
COMPLETED
Hemodynamic Effects of Rolofylline in the Treatment of Patients With Heart Failure (7418-503)
Lead Sponsor:
Merck Sharp & Dohme LLC
Collaborating Sponsors:
NovaCardia, Inc.
Conditions:
Heart Failure
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The study will estimate the effects of rolofylline, alone and in addition to loop diuretic therapy on pulmonary capillary wedge pressure and other hemodynamic parameters, in patients with heart failur...
Eligibility Criteria
Inclusion
- Patients with heart failure and renal impairment, currently using furosemide, with systolic blood pressure \>95 mm Hg
Exclusion
- Patient has active infection, use of diuretic within 3 hours of screening visit, has acute tubular necrosis or severe pulmonary disease, any heart problems within the last two weeks
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00729222
Start Date
November 1 2008
End Date
March 1 2009
Last Update
October 20 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.